Transcode Therapeutics, Inc. (RNAZ) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Transcode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs for cancer treatment. The company operates in a single segment and is classified as an emerging growth company and a smaller reporting company. Its lead therapeutic candidate, TTX-MC138, is an oligonucleotide conjugated to an iron oxide nanoparticle designed to inhibit metastatic tumor cell survival. The company recently initiated a Phase 2a clinical trial for TTX-MC138 in colorectal cancer patients.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(24,535,198) | $(16,361,915) |
| Net Loss Attributable to Common Stockholders | $(26,375,438) | $(16,361,915) |
| Net Loss Per Share (Basic & Diluted) | $(28.14) | $(32.45) |
| Cash and Cash Equivalents (End of Period) | $8,383,393 | $7,374,815 |
| Net Cash Used in Operating Activities | $(10,380,128) | $(7,291,046) |
| Accumulated Deficit | $(122,398,191) | $(79,563,831) |
| Total Assets | $151,010,103 | $162,398,689 |
| Total Liabilities | $12,651,920 | $10,518,687 |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose to $24.5 million from $7.4 million in the prior year period. This increase was driven by a one-time non-cash charge of $10.4 million for acquired in-process research and development (IPR&D) related to the Unleash license agreement, increased clinical trial spending for TTX-MC138, and higher general and administrative costs related to the Polynoma acquisition.
- Acquisition of Polynoma: In October 2025, the company acquired Polynoma, LLC (via ABCJ), adding the Seviprotimut-L vaccine candidate to its pipeline. This resulted in significant goodwill ($25.7 million) and intangible assets ($114.3 million) on the balance sheet.
- Financing Activities: The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville in April 2026. It received $950,000 from the first tranche of a convertible note. In the prior year period, the company raised approximately $8.9 million from equity sales.
- Grant Income: Grant income decreased to $161,151 from $501,529, reflecting the completion of work related to the 2024 NIH SBIR Award.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year without additional capital. Cash on hand ($8.4 million) plus proceeds from a subsequent convertible note issuance (July 2026) are projected to fund operations through approximately year-end 2026.
- Clinical Progress: The Phase 2a trial for TTX-MC138 in colorectal cancer was initiated in Q2 2026, with initial patient enrollment expected in Q3 2026. The company is also evaluating the combination of TTX-MC138 with Seviprotimut-L.
- Capital Requirements: The company expects expenses to increase substantially as it advances clinical trials and operates as a public company. It will need to raise additional capital through equity or debt financings, which may result in significant dilution.
- Nasdaq Listing: The company received a deficiency notice regarding stockholders' equity in May 2026 but regained compliance following stockholder approval of preferred stock conversions in July 2026. However, risks regarding delisting remain if market value of listed securities falls below $5 million.
- Legal Proceedings: The company is involved in litigation with Wheeler Bio, Inc., seeking approximately $9.2 million in damages. The court has ordered the dispute to arbitration, staying the litigation.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of current cash ($8.4M) plus the $4.75M proceeds from the Second Convertible Note (issued July 22, 2026) to sustain operations through year-end 2026.
- Preferred Stock Conversion: Confirm the status of the conversion of Series A, B, and C Preferred Stock into Common Stock following the July 20, 2026, stockholder meeting, which impacts equity structure and potential dilution.
- Acquisition Milestones: Monitor the achievement of milestone events for the Polynoma acquisition, which could trigger up to $95 million in contingent payments to DEFJ.
- Unleash License Expense: Note the $10.4 million non-cash R&D charge for the Unleash license; verify the valuation assumptions and future amortization or impairment risks associated with this intangible asset.
- Warrant Liabilities: Review the fair value changes of warrant liabilities and convertible notes, which significantly impact reported net loss but are non-cash items.